Kiniksa Pharmaceuticals International, plc KNSA Total Cost of Revenue
Total Cost of Revenue at other companies
Other financials
Where this comes from
Reported directly by Kiniksa Pharmaceuticals International, plc in its filing.
Tagged under the XBRL concept us-gaap:CostOfGoodsAndServicesSold.
The official record: Kiniksa Pharmaceuticals International, plc’s 10-Q, filed April 28, 2026, on SEC EDGAR. View the filing →
Ask your AI about Kiniksa Pharmaceuticals International, plc's total cost of revenue.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Kiniksa Pharmaceuticals International, plc's total cost of revenue?
- Kiniksa Pharmaceuticals International, plc (KNSA) reported total cost of revenue of $20.8M in Q1 2026.
- How has Kiniksa Pharmaceuticals International, plc's total cost of revenue changed year-over-year?
- Kiniksa Pharmaceuticals International, plc's total cost of revenue increased by 16.4% year-over-year, from $17.87M to $20.8M.
- What is the long-term trend for Kiniksa Pharmaceuticals International, plc's total cost of revenue?
- Over 4 years (2021 to 2025), Kiniksa Pharmaceuticals International, plc's total cost of revenue has grown at a 70.9% compound annual growth rate (CAGR), from $9.1M to $77.67M.
- What does total cost of revenue mean?
- The aggregate of all direct costs attributable to producing goods and delivering services that generated the company's revenue, including materials, labor, and overhead.